Journal of Cancer Research and Clinical Oncology

, Volume 140, Issue 8, pp 1305–1313 | Cite as

Heat shock protein 22 overexpression is associated with the progression and prognosis in gastric cancer

  • Xiao-shan Li
  • Qing Xu
  • Xiang-yang Fu
  • Wei-sheng Luo
Original Article – Cancer Research



The heat shock protein 22 (HSP22) is associated with tumor proliferation and protects tumor cell from apoptosis in many malignancies. However, the role of HSP22 in gastric cancer has not been thoroughly elucidated. The aim was to determine the relationship of HSP22 expression with clinicopathological parameters and prognosis in gastric cancer and estimate the alteration of HSP22 expression after neoadjuvant chemotherapy.


HSP22 and matrix metallopeptidase 9 (MMP-9) antigen expressions were evaluated by immunohistochemistry in 129 gastric carcinoma samples. Univariate and multivariate analyses were performed to determine the association between HSP22 expression and prognosis. The response of HSP22 was assessed in 47 patients who received neoadjuvant chemotherapy.


HSP22 protein expression was significantly associated with tumor size, depth invasion, lymph node metastasis and stage of disease (all P < 0.05). In univariate and multivariate analyses, HSP22 was an independent prognostic factor for both overall survival (OS) and recurrence-free survival (RFS) (P = 0.003 and P = 0.004, respectively). Furthermore, HSP22 overexpression was associated with a poor prognosis in all patients and in patients subgroups stratified by tumor size, depth invasion and lymph node metastasis. In addition, HSP22 was significantly correlated with MMP-9 among 129 gastric cancer tissues (P < 0.001). Patients who had MMP-9 overexpression had poor OS and shorter RFS. Moreover, the alteration of HSP22 was not comparable in 47 patients who underwent neoadjuvant chemotherapy.


HSP22 plays an important role on tumor aggressiveness and prognosis and may act as a promising target for prognostic prediction.


Heat shock protein 22 Gastric cancer Aggressiveness Prognosis 



Heat shock protein 22


Matrix metallopeptidase 9


Union International Cancer Control




Recurrence-free survival


Overall survival



We gratefully acknowledge the clinical data provided by the pathology department (Affiliated Hospital of Guilin Medical University). This work was supported by a Grant of National Natural Science Foundation of China (Nos. 81360530).

Conflict of interest

The authors declare that there are no conflicts of interest or financial disclosures.


  1. Al-Batran SE, Hartmann JT, Probst S et al (2008) Phase iii trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie. J Clin Oncol 26:1435–1442PubMedCrossRefGoogle Scholar
  2. Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of her2-positive advanced gastric or gastro-oesophageal junction cancer (toga): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697PubMedCrossRefGoogle Scholar
  3. Calderwood SK, Khaleque MA, Sawyer DB et al (2006) Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci 31:164–172PubMedCrossRefGoogle Scholar
  4. Charpentier AH, Bednarek AK, Daniel RL et al (2000) Effects of estrogen on global gene expression: identification of novel targets of estrogen action. Cancer Res 60:5977–5983PubMedGoogle Scholar
  5. Chu D, Zhang Z, Li Y et al (2011) Matrix metalloproteinase-9 is associated with disease-free survival and overall survival in patients with gastric cancer. Int J Cancer (Journal international du cancer) 129:887–895CrossRefGoogle Scholar
  6. Compare D, Rocco A, Nardone G (2010) Risk factors in gastric cancer. Eur Rev Med Pharmacol Sci 14:302–308PubMedGoogle Scholar
  7. Cunningham D, Allum WH, Stenning SP et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11–20PubMedCrossRefGoogle Scholar
  8. Dikken JL, van Sandick JW, Maurits Swellengrebel HA et al (2011) Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (critics). BMC Cancer 11:329PubMedCentralPubMedCrossRefGoogle Scholar
  9. Edge SB, Compton CC (2010) The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17:1471–1474PubMedCrossRefGoogle Scholar
  10. Gober MD, Wales SQ, Aurelian L (2005) Herpes simplex virus type 2 encodes a heat shock protein homologue with apoptosis regulatory functions. Front Biosci J Virtual Libr 10:2788–2803CrossRefGoogle Scholar
  11. Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69–90PubMedCrossRefGoogle Scholar
  12. Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:2137–2150PubMedCrossRefGoogle Scholar
  13. Kim HJ, Hwang NR, Lee KJ (2007) Heat shock responses for understanding diseases of protein denaturation. Mol Cells 23:123–131PubMedGoogle Scholar
  14. Modem S, Chinnakannu K, Bai U et al (2011) Hsp22 (hspb8/h11) knockdown induces sam68 expression and stimulates proliferation of glioblastoma cells. J Cell Physiol 226:2747–2751PubMedCentralPubMedCrossRefGoogle Scholar
  15. Nelson AR, Fingleton B, Rothenberg ML et al (2000) Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18:1135–1149PubMedGoogle Scholar
  16. Smith CC, Yu YX, Kulka M et al (2000) A novel human gene similar to the protein kinase (PK) coding domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) codes for a serine-threonine pk and is expressed in melanoma cells. J Biol Chem 275:25690–25699PubMedCrossRefGoogle Scholar
  17. Sun X, Fontaine JM, Rest JS et al (2004) Interaction of human HSP22 (HSPB8) with other small heat shock proteins. J Biol Chem 279:2394–2402PubMedCrossRefGoogle Scholar
  18. Uversky VN, Oldfield CJ, Dunker AK (2005) Showing your ID: intrinsic disorder as an id for recognition, regulation and cell signaling. JMR 18:343–384PubMedGoogle Scholar
  19. Wadhwa R, Ryu J, Gao R et al (2010) Proproliferative functions of drosophila small mitochondrial heat shock protein 22 in human cells. J Biol Chem 285:3833–3839PubMedCentralPubMedCrossRefGoogle Scholar
  20. Wang J, Cui S, Zhang X et al (2013) High expression of heat shock protein 90 is associated with tumor aggressiveness and poor prognosis in patients with advanced gastric cancer. PLoS ONE 8:e62876PubMedCentralPubMedCrossRefGoogle Scholar
  21. Wu AW, Xu GW, Wang HY et al (2007) Neoadjuvant chemotherapy versus none for resectable gastric cancer. Cochrane Database Syst Rev (2):CD005047Google Scholar
  22. Yang C, Trent S, Ionescu-Tiba V et al (2006) Identification of cyclin D1- and estrogen-regulated genes contributing to breast carcinogenesis and progression. Cancer Res 66:11649–11658PubMedCrossRefGoogle Scholar
  23. Zhao F, Zhang Q, Kang C et al (2010) Suppression of matrix metalloproteinase-9 expression by RNA interference inhibits SGC7901 gastric adenocarcinoma cell growth and invasion in vitro and in vivo. Med Oncol 27:774–784PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Xiao-shan Li
    • 1
  • Qing Xu
    • 2
  • Xiang-yang Fu
    • 1
  • Wei-sheng Luo
    • 1
  1. 1.Department of GastroenterologyAffiliated Hospital of Guilin Medical UniversityGuilinChina
  2. 2.Guilin Medical UniversityGuilinChina

Personalised recommendations